IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
Revenue $21.2 million in Q3 2025, a 16% increase from $18.3 million in Q3 2024. Growth driven by strong performance across product lines, particularly MRI compatible IV infusion pump systems and patient vital signs monitoring systems.
Gross Profit $16.4 million in Q3 2025, up 16% from $14.1 million in Q3 2024. Gross margin was 78%, compared to 77% in Q3 2024. Improvement attributed to strong margin performance despite moving manufacturing operations to a new facility.
Operating Expenses $9.7 million in Q3 2025, up 15% from $8.4 million in Q3 2024. Increase driven by higher sales and marketing expenses, modest increases in general and administrative costs, and research and development expenses.
Income from Operations $6.8 million in Q3 2025, a 17% increase from $5.8 million in Q3 2024. Growth attributed to higher revenue and controlled cost of goods sold.
Net Income $5.6 million or $0.43 per diluted share in Q3 2025, a 12% increase from $5 million or $0.40 per diluted share in Q3 2024. Non-GAAP net income was $6.1 million or $0.47 per diluted share, up 9% from $0.43.
Cash and Cash Equivalents $56.5 million at the end of Q3 2025, up from $52.2 million at year-end 2024. Increase driven by strong cash flow from operations.
Cash Flow from Operations $7 million for Q3 2025 and $19 million year-to-date. Free cash flow was $5.7 million for the quarter and $11 million year-to-date, reflecting capital expenditures of $8 million year-to-date.
MRI Compatible IV Infusion Pump Systems Revenue $8.3 million in Q3 2025, up 20% year-over-year. Growth driven by increased shipments and replacement orders for older pumps.
Patient Vital Signs Monitoring Systems Revenue $6.9 million in Q3 2025, up 16% year-over-year. Growth attributed to successful emphasis on monitoring sales.
Disposable Revenue $4.1 million in Q3 2025, a 12% increase year-over-year. Growth reflects increased utilization of devices.
Domestic Sales $18.1 million in Q3 2025, a 19% increase year-over-year. Domestic revenue accounted for 85% of total revenue, up from 83% in Q3 2024.
International Sales $3.1 million in Q3 2025, consistent with Q3 2024.
Trade with 70% Backtested Accuracy
Analyst Views on IRMD
About IRMD
About the author
Transcript of IRadimed (IRMD) Earnings Call for Q3 2025
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed
Upcoming Ex-Dividend Dates: Duke Energy Corp (DUK), American States Water Co (AWR), and iRadimed Corp (IRMD) will trade ex-dividend on 11/14/25, 12/2/25, and 11/25/25 respectively, with dividends of $1.065, $0.504, and $0.17.
Expected Price Adjustments: Following the ex-dividend dates, shares of DUK, AWR, and IRMD are expected to open lower by approximately 0.86%, 0.66%, and 0.20% respectively.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 3.44% for Duke Energy, 2.66% for American States Water, and 0.80% for iRadimed, reflecting their historical dividend stability.
Current Trading Performance: As of Wednesday trading, Duke Energy shares are up 0.6%, American States Water shares are up 1.1%, while iRadimed shares are down 1.7%.
